EP3334395A2 - Apparatus for reducing intraocular pressure and method for manufacturing such apparatus - Google Patents

Apparatus for reducing intraocular pressure and method for manufacturing such apparatus

Info

Publication number
EP3334395A2
EP3334395A2 EP16754612.6A EP16754612A EP3334395A2 EP 3334395 A2 EP3334395 A2 EP 3334395A2 EP 16754612 A EP16754612 A EP 16754612A EP 3334395 A2 EP3334395 A2 EP 3334395A2
Authority
EP
European Patent Office
Prior art keywords
control device
flow control
housing
aqueous humor
flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16754612.6A
Other languages
German (de)
English (en)
French (fr)
Inventor
Lucinda J. Camras
Rolf Erik Ypma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camras Vision Inc
Original Assignee
Camras Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/826,866 external-priority patent/US10342702B2/en
Application filed by Camras Vision Inc filed Critical Camras Vision Inc
Publication of EP3334395A2 publication Critical patent/EP3334395A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment

Definitions

  • aspects of the present disclosure are generally directed to an apparatus and method for draining aqueous humor from an anterior chamber of an eye to a location external or distal to the anterior chamber for reducing intraocular pressure and, more particularly, to an implantable apparatus for regulating intraocular pressure using a flow control device having an dilatable conduit for directing a flow of the aqueous humor externally of the anterior chamber of the eye to an external or distal drainage site for reducing and regulating intraocular pressure.
  • Glaucoma is a group of chronic optic nerve diseases and a leading cause of irreversible blindness.
  • the major risk factor in glaucoma is elevated intraocular pressure due to improper drainage of aqueous humor from the eye. Reduction of intraocular pressure is the only proven treatment to stop the progression of vision loss by reducing stress on the optic nerve.
  • Implantable drainage devices function to drain excess aqueous humor from the eye, and installation of such a drainage device typically requires a surgical opening made in the sclera to reach the interior of the eye, in particular the anterior chamber or the posterior chamber.
  • the drainage device is then inserted into the interior of the eye for conducting the aqueous humor to the subconjunctival space (with such a device herein referred to as a subconjunctival shunt), or externally of the conjunctiva (with such a device herein referred to as an external shunt).
  • a problem associated with subconjunctival shunts is potential scarring of the bleb in the subconjunctival space affecting its fibrous capsule formation around the outlet, which in many cases requires surgical revision that leads to additional risk of complications. Therefore, there is an ongoing search to identify and utilize alternate drainage sites to avoid many problems associated with bleb and fibrous capsule formations.
  • External shunts avoid bleb and fibrous capsule formation and the unpredictability of wound healing in the subconjunctival space.
  • the outlet of an external shunt may be perceived by the patient as a foreign body, especially those that lie on the corneal surface.
  • These shunts can also be displaced by local tissue motion or extruded by constrictive wound healing processes.
  • external shunts can expose a mechanical conduit available to transmit microorganisms from the outside to the interior of the eye, potentially leading to retrograde infection.
  • All drainage devices implanted in the eye have the potential to clog from proteins or other substances in the aqueous humor. Clogging reduces permeability of the device and may lead to elevation of intraocular pressure compared to baseline. Moreover, the intraocular pressure may naturally vary or fluctuate due to changes in aqueous humor dynamics of the particular eye, regardless of the effect of a drainage device.
  • an apparatus for draining aqueous humor from an eye for reducing or stabilizing intraocular pressure wherein the eye includes an anterior chamber, a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an external ocular surface of the eye under an eyelid.
  • Such an apparatus may comprise a tube extending between an inlet end and an outlet end, with the inlet end being adapted to be in fluid communication with the anterior chamber of the eye, and with the tube being adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end to the outlet end.
  • a housing defines a cavity in fluid communication with the outlet end of the tube, wherein the cavity is configured to receive the aqueous humor.
  • a flow control device is operably engaged with the housing and is configured to control the flow of the aqueous humor from the cavity to a location external or distal to the anterior chamber.
  • the flow control device defines a conduit in communication between the cavity and the external location, wherein the conduit is dilatable in response to the intraocular pressure being above a preselected pressure, to increase the flow or to decrease resistance to flow of the aqueous humor through the conduit to the external location and to reduce the intraocular pressure to no greater than the preselected pressure.
  • Another aspect of the present disclosure provides a method of manufacturing an apparatus for draining aqueous humor from an eye for reducing or stabilizing intraocular pressure, wherein the eye includes an anterior chamber, a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an external ocular surface of the eye under an eyelid.
  • Such a method comprises engaging an outlet end of a tube into fluid communication with a cavity defined by a housing, with the outlet end extending to an inlet end adapted to be in fluid communication with the anterior chamber of the eye, and with the tube being adapted to direct the flow of aqueous humor from the anterior chamber and through the inlet end and to the outlet end such that the aqueous humor is received by the cavity.
  • a dilatable flow control device is engaged with the housing, wherein the dilatable flow control device is adapted to control a flow of the aqueous humor from the cavity to a location external or distal to the anterior chamber, and wherein the flow control device defines a conduit in communication between the cavity and the external location, the conduit being dilatable in response to the intraocular pressure being above a preselected pressure, to increase the flow or to decrease resistance to flow of the aqueous humor through the conduit to the external location and to reduce the intraocular pressure to no greater than the preselected pressure.
  • Still another aspect of the present disclosure provides an apparatus for draining aqueous humor from an eye for reducing or stabilizing intraocular pressure, wherein the eye includes an anterior chamber, a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an external ocular surface of the eye under an eyelid.
  • Such an apparatus comprises a tube extending between an inlet end and an outlet end, with the inlet end being adapted to be in fluid communication with the anterior chamber of the eye, and with the tube being adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end to the outlet end.
  • a flow control device is operably engaged with the outlet end and is configured to control the flow of the aqueous humor from the tube to a location external to the anterior chamber.
  • the flow control device defines a conduit in communication between the outlet end and the external location, wherein the conduit is dilatable in response to the intraocular pressure being above a preselected pressure, to increase the flow or to decrease resistance to flow of the aqueous humor through the conduit to the external location and to reduce the intraocular pressure to no greater than the preselected pressure.
  • a first filter device is disposed in fluid communication between the inlet end of the tube and the flow control device, wherein the filter device is configured to filter contaminants from the aqueous humor prior to the flow control device.
  • a second filter device is disposed in fluid communication with the flow control device, opposite to the outlet end of the tube from the flow control device, wherein the second filter device is configured to filter contaminants from any backflow to the flow control device.
  • Embodiment 1 An apparatus for draining aqueous humor from an eye for reducing or stabilizing intraocular pressure, the eye having an anterior chamber and including a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an external ocular surface of the eye under an eyelid, the apparatus comprising a tube extending between an inlet end and an outlet end, the inlet end being adapted to be in fluid communication with the anterior chamber of the eye, and the tube being adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end to the outlet end; a housing defining a cavity in fluid communication with the outlet end of the tube, the cavity being configured to receive the aqueous humor; and a flow control device operably engaged with the housing and configured to control the flow of the aqueous humor from the cavity to a location external to the anterior chamber, the flow control device defining a conduit in communication between the cavity and the external location, the conduit being dilatable in
  • Embodiment 2 The apparatus of any preceding or subsequent embodiment, or combinations thereof, comprising a filter device disposed in fluid communication between the inlet end of the tube and the flow control device, the filter device being configured to filter contaminants from the aqueous humor prior to the flow control device.
  • Embodiment 3 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the filter device is engaged with the housing subsequent to the outlet end of the tube, and wherein the housing is configured such that the flow control device operably engaged therewith is removable or replaceable with respect to the housing, so as to allow the filter device to be removed or replaced.
  • Embodiment 4 The apparatus of any preceding or subsequent embodiment, or combinations thereof, comprising a filter device disposed in fluid communication with the flow control device, opposite to the outlet end of the tube from the flow control device, the filter device being configured to filter contaminants from any backflow to the flow control device.
  • Embodiment 5 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the filter device is engaged with the housing subsequent to the flow control device, and wherein the housing is configured such that the filter device engaged therewith is removable or replaceable with respect to the housing.
  • Embodiment 6 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device defines a plurality of conduits in communication between the cavity and the external location, and wherein at least one of the conduits is dilatable.
  • Embodiment 7 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the conduits are arranged in parallel and in communication between the cavity and the external location.
  • Embodiment 8 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the conduit comprises a single inlet port in fluid communication with the cavity defined by the housing, and a plurality of outlet ports each in fluid communication with the inlet port through respective channels extending from the inlet port.
  • Embodiment 9 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the channels extend radially outward from the single inlet port such that the outlet ports are angularly spaced apart about the inlet port.
  • Embodiment 10 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device includes a first portion defining a single inlet port in fluid communication with the cavity defined by the housing, and a second portion defining a plurality of outlet ports, the first and second portions being configured to be complementarily engaged so as to define a reservoir therebetween, with the outlet ports each being in fluid communication with the inlet port via the reservoir.
  • Embodiment 11 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the second portion is rigid so as to resist deformation in response to a force applied thereto.
  • Embodiment 12 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device is configured to be responsive to an output of a laser device so as to form additional dilatable conduits therein.
  • Embodiment 13 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device is configured to be responsive to an output of a laser device to seal a conduit defined thereby.
  • Embodiment 14 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the housing is configured such that the flow control device operably engaged therewith is removable or replaceable with respect to the housing.
  • Embodiment 15 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device is disposed within the cavity defined by the housing.
  • Embodiment 16 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the housing defines an aperture opposite the flow control device from the outlet end of the tube, the aperture being in fluid communication with the cavity so as to permit egress of aqueous humor therethrough to the external location.
  • Embodiment 17 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the conduit is configured to be constrictable in response to the intraocular pressure being below the preselected pressure, to decrease the flow or to increase resistance to the flow of the aqueous humor through the conduit to the external location and to increase the intraocular pressure to no greater than the preselected pressure.
  • Embodiment 18 The apparatus of any preceding or subsequent embodiment, or combinations thereof, further comprising an anchoring device operably engaged with the housing, the anchoring device being configured to engage the eye subconjunctivally so as to secure at least the housing to the eye.
  • Embodiment 19 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the conduit is configured to be normally constricted to prevent flow of the aqueous humor therethrough.
  • Embodiment 20 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device is comprised of a biocompatible material.
  • Embodiment 21 The apparatus of any preceding or subsequent embodiment, or combinations thereof, wherein at least a portion of the flow control device defining the conduit is comprised of polyurethane or silicone.
  • Embodiment 22 A method of manufacturing an apparatus for draining aqueous humor from an eye for reducing or stabilizing intraocular pressure, the eye having an anterior chamber and including a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an external ocular surface of the eye under an eyelid, the method comprising engaging an outlet end of a tube into fluid communication with a cavity defined by a housing, the outlet end extending to an inlet end adapted to be in fluid communication with the anterior chamber of the eye, the tube being adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end and to the outlet end such that the aqueous humor is received by the cavity; and engaging a dilatable flow control device with the housing, the dilatable flow control device being adapted to control the flow of the aqueous humor from the cavity to a location external to the anterior chamber, and defining a conduit in communication between the cavity and the external location, the conduit being di
  • Embodiment 23 The method of any preceding or subsequent embodiment, or combinations thereof, comprising disposing a filter device into fluid communication between the inlet end of the tube and the flow control device, for filtering contaminants from the aqueous humor prior to the flow control device.
  • Embodiment 24 The method of any preceding or subsequent embodiment, or combinations thereof, comprising engaging the filter device with the housing subsequent to the outlet end of the tube, such that the flow control device is removable or replaceable with respect to the housing, so as to allow the filter device to be removed or replaced.
  • Embodiment 25 The method of any preceding or subsequent embodiment, or combinations thereof, comprising engaging a filter device into fluid communication with the flow control device, opposite to the outlet end of the tube from the flow control device, for filtering contaminants from any backflow to the flow control device.
  • Embodiment 26 The method of any preceding or subsequent embodiment, or combinations thereof, comprising engaging the filter device with the housing subsequent to the flow control device, such that the filter device engaged therewith is removable or replaceable with respect to the housing.
  • Embodiment 27 The method of any preceding or subsequent embodiment, or combinations thereof, wherein engaging a dilatable flow control device with the housing comprises engaging a dilatable flow control device with the housing, wherein the flow control device defines a plurality of conduits in communication between the cavity and the external location, and wherein at least one of the conduits is dilatable.
  • Embodiment 28 The method of any preceding or subsequent embodiment, or combinations thereof, wherein engaging a dilatable flow control device with the housing comprises engaging a dilatable flow control device with the housing, wherein the flow control device defines a plurality of conduits arranged in parallel and in communication between the cavity and the external location.
  • Embodiment 29 The method of any preceding or subsequent embodiment, or combinations thereof, wherein engaging a dilatable flow control device with the housing comprises engaging a dilatable flow control device with the housing, wherein the conduit comprises a single inlet port in fluid communication with the cavity defined by the housing, and a plurality of outlet ports each in fluid communication with the inlet port through respective channels extending from the inlet port.
  • Embodiment 30 The method of any preceding or subsequent embodiment, or combinations thereof, wherein engaging a dilatable flow control device with the housing comprises engaging a dilatable flow control device with the housing, wherein the channels extend radially outward from the single inlet port such that the outlet ports are angularly spaced apart about the inlet port.
  • Embodiment 31 The method of any preceding or subsequent embodiment, or combinations thereof, wherein the flow control device includes a first portion defining a single inlet port in fluid communication with the cavity defined by the housing, and a complementarily-configured second portion defining a plurality of outlet ports, and wherein the method comprises engaging the first and second portions to define a reservoir therebetween, and such that the outlet ports are each in fluid communication with the inlet port via the reservoir.
  • Embodiment 32 The method of any preceding or subsequent embodiment, or combinations thereof, comprising engaging the flow control device with an output of a laser device so as to form additional dilatable conduits in the flow control device.
  • Embodiment 33 The method of any preceding or subsequent embodiment, or combinations thereof, comprising engaging the flow control device with an output of a laser device so as to seal a conduit defined by the flow control device.
  • Embodiment 34 The method of any preceding or subsequent embodiment, or combinations thereof, wherein engaging a dilatable flow control device with the housing comprises inserting a dilatable flow control device into the cavity defined by the housing.
  • Embodiment 35 An apparatus for draining aqueous humor from an eye for reducing or stabilizing intraocular pressure, the eye having an anterior chamber and including a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an external ocular surface of the eye under an eyelid, the apparatus comprising a tube extending between an inlet end and an outlet end, the inlet end being adapted to be in fluid communication with the anterior chamber of the eye, and the tube being adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end to the outlet end; a flow control device operably engaged with the outlet end and configured to control the flow of the aqueous humor from the tube to a location external to the anterior chamber, the flow control device defining a conduit in communication between the outlet end and the external location, the conduit being dilatable in response to the intraocular pressure being above a preselected pressure, to increase the flow or to decrease resistance to flow of the aque
  • Embodiment 36 The method of any preceding or subsequent embodiment, or combinations thereof, wherein the first filter device is engaged with the outlet end of the tube, and wherein the flow control device is operably engaged with the first filter device such that the flow control device is removable or replaceable with respect thereto, so as to allow the first filter device to be removed or replaced.
  • Embodiment 37 The method of any preceding or subsequent embodiment, or combinations thereof, wherein the second filter device is engaged with the flow control device opposite to the first filter device, and wherein the flow control device is configured such that the second filter device is removable or replaceable with respect thereto, so as to allow the second filter device to be removed or replaced.
  • Embodiment 38 The method of any preceding or subsequent embodiment, or combinations thereof, comprising a housing defining a cavity in fluid communication with the outlet end of the tube, the cavity being configured to receive the aqueous humor, and the housing being configured to operably engage the flow control device such that the flow control device regulates the flow of the aqueous humor from the cavity.
  • FIG. 1 is a perspective view of an embodiment of a drainage device for reducing intraocular pressure
  • FIG. 2 is an exploded perspective view of the drainage device as shown in FIG. 1 ;
  • FIG. 3 is a longitudinal cross-section elevation view of the drainage device as shown in FIG. 1;
  • FIG. 4 is a perspective schematic view of the drainage device as shown in FIG. 1 implanted in an eye;
  • FIG. 5 is a side elevation view of the drainage device implanted in an eye as shown in FIG. 4;
  • FIGS. 6A-6C schematically illustrate a drainage device, according to various embodiments of the present disclosure
  • FIG. 7 is a perspective view of an alternate embodiment of a drainage device for reducing intraocular pressure
  • FIG. 8 is an exploded perspective view of the drainage device as shown in FIG. 7;
  • FIG. 9 is a longitudinal cross-section elevation view of the drainage device as shown in FIG. 7;
  • FIG. 10 is a perspective schematic view of the drainage device as shown in FIG. 7 implanted in an eye;
  • FIGS. 1 lA-11C schematically illustrate dilation configurations of a conduit defined by a flow control device associated with a drainage device, perpendicularly to the direction of flow of a fluid therethrough, according to one embodiment of the present disclosure;
  • FIGS. 12A and 12B schematically illustrate dilation configurations of a conduit defined by a flow control device associated with a drainage device, parallel to the direction of flow of a fluid therethrough, according to one embodiment of the present disclosure
  • FIG. 13 schematically illustrates a cutaway view of a drainage device, according to one embodiment of the present disclosure
  • FIGS. 14, 15A, and 15B schematically illustrate configurations of flow control device for a drainage device, according to various embodiments of the present disclosure
  • FIGS. 16A and 16B schematically illustrate configurations of two-piece flow control device for a drainage device, according to various embodiments of the present disclosure
  • FIG. 17 schematically illustrates a method of manufacturing a drainage device, according to one aspect of the present disclosure.
  • FIG. 18 schematically illustrates a dual filter configuration of a drainage device, according to one embodiment of the present disclosure.
  • FIG. 1 schematically illustrates an implantable ocular drainage device, generally designated as element 30, according to one aspect of the present disclosure.
  • the drainage device 30 comprises a tubular body 32 and an outlet assembly 34.
  • the tubular body 32 includes an inlet end 44 and a longitudinally- opposed outlet end 42, and is configured to direct a fluid between the inlet 44 and outlet 42 ends.
  • At least a portion of the tubular body 32 of the drainage device 30 is implantable into the anterior chamber of an eye for draining aqueous humor therefrom (see, e.g., FIGS. 4 and 5).
  • the tubular body 32 of the drainage device 30 is substantially cylindrical and hollow, and has a proximal (outlet) end 42 and a distal (inlet) end 44.
  • the tubular body 32 defines a lumen 46 that extends between the proximal end 42 and the distal end 44 with the distal end defining at least one opening 48 communicating with the lumen 46.
  • the at least one opening 48 is configured to provide a fluid inlet at the distal end 44 of the tubular body 32.
  • the distal end 44 of the tubular body 32 may be beveled for facilitating entry of the distal end 44 into the anterior chamber or other portion of the eye.
  • the lumen 46 forms at least a portion of a flow path that permits the drainage of aqueous humor from the anterior chamber of the eye to a location external to the anterior chamber.
  • the external location may be an external ocular surface of the eye.
  • the external location may include another chamber within the eye, the subconjunctival space, the suprachoroidal space, or the like.
  • the tubular body 32 has a length sufficient to provide fluid communication between the anterior chamber of the eye and the fornix or cul-de-sac region under the eyelid to allow aqueous humor to flow from the anterior chamber through the lumen 46 and into the tear film associated with the eye when the drainage device 30 is implanted in or attached to the eye.
  • the tubular body 32 of the drainage device 30 may have a minimum length, for example, of at least about 3 mm for the outlet assembly 34 to be positioned about the fornix or cul-de-sac region under the eyelid. In one aspect, the tubular body 32 may have a length of between about 4 mm and about 9 mm for adult humans. In use, the tubular body 32 may lie substantially underneath the conjunctiva with the distal (input) end disposed in the anterior (or posterior) chamber of the eye (see, e.g., FIGS. 4 and 5).
  • the dimensions and deployment location of the drainage device 30 may vary considerably depending on the location to which the aqueous humor drained from the anterior chamber is directed.
  • the transverse / lateral cross-sectional shape of the tubular body 32 in addition to circular as shown in FIGS. 1-5, may be other suitable shapes such as, for example, oval, square, trapezoidal, rectangular, or any combination thereof.
  • the cross-sectional size of the lumen 46 defined by the tubular body 32 may vary to selectively alter the fluid flow characteristics of the aqueous humor.
  • a relatively small cross-sectional size can be used to restrict the fluid flow of the aqueous humor.
  • the cross-sectional dimension of the lumen 46 may range, for example, from about 0.05 mm to about 1.0 mm.
  • One or more barbs 50 may be provided adjacent the distal end 44 of the tubular body 32.
  • the barbs 50 can extend from a portion of the outer surface of the tubular body 32 for contact with the sclera when the drainage device 30 is implanted or engaged with the eye.
  • the barbs 50 are adapted to engage the sclera and provide stability until biointegration of the tubular body 32 in the subconjunctival space.
  • the barbs 50 may be formed as part of the tubular body 32 of the drainage device 30 during manufacture or may be subsequently fused or bonded to the tubular body 32 in an appropriate manner.
  • the head portion 36 of the outlet assembly 34 defines an interior cavity 52.
  • the head portion 36 is integral with, or attached to, the proximal (outlet) end 42 of the tubular body 32 such that the cavity 52 is in fluid communication with the lumen 46 of the tubular body 32 so as to receive a flow of the aqueous humor therefrom.
  • the head portion 36 and the tubular body 32 may be formed integrally as a single unit. Alternatively, each component may be formed separately from the other.
  • the head portion 36 may be dome-shaped (or convex) to provide a substantially continuous transition surface from along an outer surface of the head portion 36 to the surface of the eye (i.e., the convex curvature is configured to make a smooth transition to the surface of the eye).
  • a configuration/ shape of the head portion 36 may be better tolerated by the patient, if the head portion does not feel like a foreign object in the eye in relation to the eyelid.
  • Other shapes of the head portion 36 may be suitable and appropriate for providing similar sensory perception for the user.
  • a minimally protruding, substantially flat head portion 36 with rounded edges may be equally well tolerated.
  • Other appropriate designs may be determined by those skilled in the art.
  • the inner (convex) surface of the head portion 36 may be flat or curved (or a combination of both), as appropriate, to correspond to the shape of the external surface of the sclera where the drainage device 30 is to be positioned.
  • the head portion 36 may further comprise integral tabs 54 extending outward from an axis extending through the drainage device 30.
  • the tabs 54 may be separately-formed pieces attached to the head portion 36. If the tabs 54 are separately-formed pieces, the tabs 54 may be comprised of a flexible biocompatible material, such as silicone or polyurethane, which may be readily deformable in compliance with eye movement. As further disclosed herein, the tabs 54 may function to stabilize the position of the drainage device 30 (i.e., by way of the head portion 36) with respect to the eye, and may thus prevent extrusion of the drainage device 30 from its intended location with respect to the eye, while also possibly reducing ocular surface irritation and/or conjunctival erosion.
  • the drainage device 30 may comprise a filter 40 and/or a flow control device 39 for maintaining and/or controlling intraocular pressure and for allowing for a more physiological dynamic of the aqueous humor.
  • the head portion 36 of the outlet assembly 34 may be configured to house the flow control device 39, or may otherwise define an opening for receiving the flow control device 39, through which opening the filter 40 may be inserted into and/or removed from the head portion 36.
  • FIGS. 2 and 3 schematically illustrate, for example, a filter 40 at least partially disposed within the head portion 36 and the lumen 46 at the proximal end 42 of the tubular body 32 of the drainage device 30.
  • the filter 40 may be configured as an elongate member having a distal inflow end 44 and a proximal outflow end 42.
  • the filter 40 may be configured to extend laterally across the lumen 46 such that the lumenal passage of the tubular body 32 is closed or substantially closed by the filter 40.
  • the aqueous humor flowing through the lumen 46 is therefore directed through the filter 40, wherein the filter 40 filters the aqueous humor to prevent bacterial migration in either direction along the lumen.
  • the filter 40 may also be configured to regulate or at least facilitate the regulation of intraocular pressure by providing a predetermined resistance to outflow of aqueous humor from the anterior chamber of the eye to the external location (i.e., into the tear film about the exterior surface of the eye).
  • the filter 40 may be configured as a resistive component for the flow of aqueous humor. That is, the filter can provide particular flow rate of aqueous humor by selecting filter characteristics such as a predetermined number and size of pores and a selected overall length of the filter 40 (i.e., the flow path). These parameters, either separately or in combination, may be configured to provide an appropriate resistance to the flow of aqueous humor sufficient to reduce and maintain intraocular pressure, while preventing ocular hypotony.
  • the filter 40 may have a gradient of pore sizes along the length of the filter 40.
  • the pore size may continually decrease from the distal end 44 of the filter 40 to the proximal end 42 in order to prevent debris accumulation at the distal (inlet) end 44 of the filter 40.
  • Larger pores sizes at the distal end 44 and at the proximal end 42 of the filter 40 may provide a pore gradient, which may help to reduce the effect of clogging on the outflow resistance.
  • the filter 40 may be removable and replaceable, and may be facilitated by external access to the outlet assembly 34, without disrupting the position of the drainage device 30 in the eye (i.e., the tubular body 32).
  • the ocular pressure can be regulated by selecting a filter configuration that provides a selected aqueous humor flow rate.
  • the filter 40 may be configured to form a permanent element of the drainage device 30.
  • a flow control device 39 may be housed by, in fluid communication with, or otherwise operably engaged with the head portion 36 (i.e., a housing defined and provided by the head portion 36). If the filter 40 is implemented in such aspects, the filter 40 may be disposed in fluid communication between the inlet (distal) end 44 of the tubular body 32 and the flow control device 39, with the filter 40 being configured to filter contaminants from the aqueous humor prior to the flow control device 39.
  • the filter 40 may be engaged with the housing of the head portion 36 subsequent to the outlet (proximal) end 42 of the tubular body (or "tube") 30, and wherein the housing of the head portion 36 is configured such that the flow control device 39 operably engaged therewith is removable or replaceable with respect to the housing, so as to allow the filter 40 to be removed or replaced.
  • the filter 40 may be disposed in fluid communication with the flow control device 39, opposite to the outlet (proximal) end 42 of the tubular body 32 from the flow control device 39, wherein the filter 40 is configured to filter contaminants from any backflow to the flow control device 39.
  • the filter 40 may be engaged with the housing of the head portion 36 subsequent to the flow control device 39, and wherein the housing may be configured such that the filter 40 engaged therewith is removable or replaceable with respect to the housing.
  • the head portion / housing 36 may be configured to define a cavity 52 therein, wherein the flow control device 39 may be configured to control a flow of the aqueous humor from the cavity 52 to the external ocular surface of the eye.
  • the flow control device 39 defines a conduit 38 in communication between the cavity 52 and the external ocular surface.
  • the flow control device 39 may comprise a relatively thin and flexible membrane defining a conduit 38 in the form of an elongate slit (see, e.g., FIGS. 1 and 2), wherein the flexible membrane is configured to deform about a medial portion along the length of the slit, in response to elevated intraocular pressure, to allow aqueous humor to exit the drainage device 30.
  • the flow control device 39 may comprise an elongate or relatively thick portion defining a conduit 38 extending through the thickness.
  • the conduit 38 is dilatable in response to the intraocular pressure being above a preselected or threshold pressure, to increase the flow or to decrease resistance to flow of the aqueous humor through the conduit 38 to the external location (i.e., the external ocular surface) and to reduce and/or stabilize the intraocular pressure to no greater than the preselected pressure.
  • the configuration of the dilatable conduit 38 may be determined according to a preselected intraocular pressure, wherein the preselected ocular pressure may be a factor of, for example, the patient' s age, physical characteristics, characteristics of the eye, advancement of the condition, particular physiological dynamics, or the like that are particular to a particular patient.
  • the lateral cross-section of the conduit 38 may take different forms such as, for example, circular, ovular, square, rectangular, or any other suitable shape, whether regular or irregular.
  • the flow control device 39 may be disposed within the cavity 52 defined by the housing of the head portion 36.
  • the housing may define an aperture 80 opposite the flow control device 39 from the outlet end 42 of the tubular body 32, with the aperture 80 being in fluid communication with the cavity 52 so as to permit egress of aqueous humor through the flow control device 39 and the aperture 80, to the external location.
  • a filter 40 may be disposed subsequent to (i.e., downstream) of the flow control device 39, opposite to the outlet (proximal) end 42 of the tubular body 32 from the flow control device 39.
  • the filter 40 may be engaged with the aperture 80 about the outlet of the head portion 36.
  • the filter 40 may be configured to filter contaminants from any backflow to the flow control device 39, to preclude external contaminants from reaching the flow control device 39, or such that the filter 40 cooperates with the flow control device 39 to resist or prevent bacterial incursion into the tubular body 32 leading to the interior of the eye.
  • At least the portion of the flow control device 39 defining the conduit 38 may be configured to dilate in response to the intraocular pressure being above a preselected pressure (see, e.g., FIGS. 1 lA-11C, and 12A-12B). Such dilation or expansion of the cross-sectional area of the conduit 38 allows a flow, or an increase in the flow, or a decrease in the resistance to the flow, of the aqueous humor through the conduit 38 to the external location, thereby reducing and/or stabilizing the intraocular pressure to less than or equal to the preselected pressure. That is, at least the portion of the flow control device 39 defining the conduit 38 may be configured to have pressure -responsive dilation properties.
  • At least the portion of the flow control device 39 defining the conduit 38 may be configured to have an actuator (not shown) engaged therewith, with the actuator being configured to cause dilation of at least the portion of the flow control device 39 defining the conduit 38.
  • at least the portion of the flow control device 39 defining the conduit 38 may be configured such that the conduit 38 is normally constricted to prevent flow of the aqueous humor therethrough (i.e., the conduit 38 is normally closed).
  • the conduit 38 may also be configured to be constrictable or to constrict, in response to decreased aqueous humor production causing the intraocular pressure to fall below the preselected pressure, to decrease or halt the flow or to increase resistance to flow of the aqueous humor through the conduit 38 to the external location and thereby allowing the intraocular pressure to increase to no greater than the preselected pressure.
  • This pressure- responsive dilation property of the portion of the flow control device 39 defining the conduit 38 may thus be operable to regulate the flow of the aqueous humor and thus not only reduce the intraocular pressure into accordance with the preselected pressure, but also facilitate stabilization of the intraocular pressure regardless of the particular patient's aqueous humor dynamic properties (i.e., individual rate of production of the aqueous humor depending on the day or time of day).
  • the flow control device 39 may be configured to define a plurality of conduits 38 in communication between the cavity 52 and the external location (see, e.g., FIGS. 15A and 15B).
  • at least one of the conduits 38 is dilatable, for example, in response to intraocular pressure exceeding a preselected pressure or upon actuation of the dilation by an appropriate actuator (not shown).
  • the plurality of conduits 38 may be arranged in parallel and in communication between the cavity 52 and the external location. As shown in FIG.
  • the conduit 38 may comprise, for instance, a single inlet port 200 in fluid communication with the cavity 52 defined by the housing, and a plurality of outlet ports 220 each in fluid communication with the inlet port 200 through respective channels 210 extending from the inlet port 200.
  • the channels 210 may be configured to extend radially outward from the single inlet port 200 such that the outlet ports 220 are angularly spaced apart about the inlet port 200.
  • the flow control device 39 may include a first portion 230 defining a single inlet port 200 in fluid communication with the cavity 52 defined by the housing of the head portion 36, and a second portion 240 defining a plurality of outlet ports 220.
  • the first and second portions 230, 240 are configured to be complementarily engaged so as to define a reservoir 250 therebetween, wherein the outlet ports 220 are each in fluid communication with the inlet port 200 via the reservoir 250. Since the second portion 240 defines the outlet ports 220, and may thus be directed outwardly of the head portion 36, the second portion 240 may be configured to be relatively rigid so as to resist deformation in response to a force applied thereto.
  • the first and second portions 230, 240 may be configured to be responsive, for example, to an output of a laser device (not shown) so as to attach the components together.
  • the housing of the head portion 36 may be configured such that the flow control device 39 operably engaged therewith is removable or replaceable with respect to the housing. That is, the flow control device 39 may be removable/replaceable with respect to the housing, whether disposed within the cavity 52, or engaged with the aperture 80 defined by the housing. Further, the flow control device 39 maybe removable / replaceable with respect to the housing, whether or not a filter 40 is disposed subsequently to /downstream of the flow control device 39. In addition, the flow control device 39 may be removable / replaceable with respect to the housing, in order that a filter 40 disposed upstream of the flow control device 39 (i.e., in engagement with the outlet end 42 of the tubular body 32) may also be removable / replaceable.
  • the drainage device 100 may comprise a tubular body 102 and an outlet assembly 104, wherein the outlet assembly 104 includes a head portion 106 defining an opening 108 configured for insertion and removal of a filter 110 into the head portion 106.
  • a removable circular cap 109 having a flow control device 150 engaged therewith, is provided for sealing the opening 108 and for accessing the interior of the head portion 106 via a conduit (shown, for example, as slit 112, though any of the flow control device configurations disclosed herein having a dilatable conduit may be applied).
  • At least a portion of the tubular body 102 of the drainage device 100 is implantable into the anterior chamber of an eye for draining aqueous humor therefrom.
  • the tubular body 102 of the drainage device 100 may be substantially ovular and defines a lumen 114 that extends between a proximal end 116 and the distal end 118 of the tubular body 102.
  • the distal end 118 of the tubular body 102 defines at least one opening 120 communicating with the lumen 114 and functioning as a fluid inlet.
  • One or more tapered projections 122, or barbs, may be provided adjacent the distal end 118 of the tubular body 102.
  • the head portion 106 of the outlet assembly 104 may further comprise integral radial tabs 124 extending outwardly from a longitudinal axis of the drainage device 100.
  • the head portion 106 may define an interior cavity 126 in fluid communication with the lumen 114 of the tubular body 102, wherein the interior cavity 126 is configured to accommodate and receive the filter 110.
  • a circular rim 128 extends radially outward of the surface of the head portion 106 for defining the opening 120.
  • the filter 110 is disposed within the head portion 106 and is configured such that the outlet of the lumenal passage of the tubular body 102 is closed or substantially closed or otherwise occupied by the filter 110.
  • the filter 110 is configured to prevent bacterial migration toward the interior of the eye, and may be configured to regulate or facilitate regulation of intraocular pressure by providing a predetermined resistance to outflow of aqueous humor from the anterior chamber of the eye toward the external location (i.e., the tear film).
  • the flow control device 150 in the cap 109 may be configured to permit the outflow of aqueous humor that has passed through the filter 110 to flow outward to the external location (i.e., onto the sclera and to enter the tear film), while providing resistance to aqueous humor outflow and restriction against backflow or bacterial incursion.
  • the flow control device 39 may be comprised of a flexible biocompatible material such as, for example, polyurethane or silicone.
  • the flow control device 39, or the material from which the flow control device 39 is comprised may be configured to be responsive, for example, to an output of a laser device (not shown) so as to form or open additional dilatable channels therein or to attach components together. That is, a laser light output directed at the material comprising the flow control device 39 may cause the formation or opening of additional conduits 38, as necessary or desired for controlling the flow of aqueous humor from the eye, and thus controlling the intraocular pressure.
  • the flow control device 39 may also be configured to be responsive, for instance, to the output of the laser device to seal or constrict a conduit 38 defined thereby. That is, one or more of the conduits 38 can be sealed or constricted, as necessary or desired, to control the flow or manipulate the resistance to flow of aqueous humor from the eye.
  • the laser modification of the conduits defined by the flow control device 39, or the material from which the flow control device 39 is comprised may be accomplished in situ, with the drainage device 30 in place with respect to the eye.
  • the flow control device 39 may be fabricated by any suitable microfabrication technique or process, in addition or in the alternative to the responsiveness thereof to the output of a laser device. For example,
  • photolithography / deposition techniques casting, molding, or any other suitable technique or combinations thereof may be implemented for forming the flow control device 39.
  • the flow control device 39 may be configured to open (dilate) and close (constrict) to regulate and/or stabilize the flow of the aqueous humor from the interior cavity 52 of the head portion 36 to the external location (i.e., to flow onto the sclera and enter the tear film) and, in doing so, maintains the intraocular pressure within a normal range of about 7 mmHg to about 20 mmHg.
  • the conduit 38 when the intraocular pressure exceeds a preselected pressure, the conduit 38 will dilate, or is actuated to dilate, and permit the aqueous humor to exit the outlet assembly 34 (i.e., by reducing or decreasing the resistance to flow of the aqueous humor).
  • the conduit 38 When the intraocular pressure is reduced below the preselected pressure, due to the flow of the aqueous humor through and from the outlet assembly 34, the conduit 38 will constrict to its normal state (closed or partially open) and limit, or inhibit, the aqueous humor from exiting the head portion 36 (i.e., increase the resistance to flow of the aqueous humor).
  • the conduit 38 will remain in its normal state (closed or partially open) until the intraocular pressure again reaches or exceeds the preselected pressure, at which time the conduit 38 will re-dilate to permit, or enhance, further drainage or reduced resistance to flow of the aqueous humor.
  • the portion of the flow control device 39 defining the conduit 38 may be configured to be dilatable in the direction of flow of the aqueous humor, or perpendicularly to the direction of flow of the aqueous humor.
  • conduit(s), channel(s), and port(s) associated with the flow control device 39 are formed with micro-scale or nano-scale relative dimensions, and the manufacturing techniques and processes implemented in the production thereof are therefore selected accordingly.
  • the drainage device 30 provides drainage of the anterior chamber of the eye through the drainage device 30, based on the intraocular pressure, and reduces the likelihood for over-draining the anterior chamber and causing hypotony.
  • the flow control device 39 with essentially a oneway (anti-backflow) valve structure, prevents backflow of the aqueous humor.
  • a pressure-actuated check valve may be implemented consistently with the application parameters disclosed herein.
  • tubular body and the outlet assembly of the embodiments of drainage device 30, 100 may be formed from materials having good biocompatibility and durability, and which are sufficiently flexible.
  • Suitable materials include a material selected from the group consisting of silicone, acrylic, polyimide, polypropylene, polymethyl methacrylate, polytetrafluoroethylene, hydrogels, polyolefin, polyolefin resins such as polyethylene, polyisobutylene, ethylene- vinyl acetate copolymer, polynorbornene, polyvinylchloride, polyester, polyvinyl alcohol, polyvinyl pyrolidone, polyethersulfone (PES), poly(styrene-isobutyl-styrene), polysilicon, polyurethane, polycarbonate urethane, glass and ceramics such as alumina and titania, metals such as stainless steel, titanium, gold, silver, platinum or nitinol, collagen or chemically-treated collagen,
  • At least a portion of the filter(s) 40 has a pore size that is sufficiently small to prevent ingress or backflow of microorganisms, such as bacteria, viruses, fungi and spores thereof, from entering the lumen 46, so as to minimize the opportunity for reflux infection in the eye.
  • a pore size of less than about 0.4 ⁇ is sufficiently small to prevent ingress or backflow of microorganisms.
  • the filter 40 may comprise a microporous/nanoporous membrane or polymer network, fiber network, or microcapsular material having a network of pores.
  • Microporous filter membranes suitable for use with ophthalmic devices include micropore filter membranes (polycarbonate, polyethersulfone, polyvinylidene fluoride, polytetrafluoroethylene), porous hydrogels (polyacrylamide, alginate, polyhydroxyethylmethacrylate), and microperforated silicone or polyvinyl polymer, such as polyvinyl alcohol, which is expandable within the lumen 46.
  • Other suitable polymers include a polyolefin polymer, an ethylene-vinyl alcohol copolymer, a polyacrylonitrile polymer, a cellulose polymer, cellulose acetate polymer, and a polyamide polymer.
  • Filter membrane nanotechnology may also be useful to fabricate microporous membranes to be biocompatible, non-degradable, and immune-isolating.
  • Other materials such as ceramics, polymers and metals, such as titanium, may also be suitable for the filter.
  • the filters may be created using lithography or
  • the filter 40, 110 may have an antibiotic coating to prevent contamination during replacement. Suitable coatings for the filter are described in co-pending U.S. Patent Application Publication No. 2010/0057055, the contents of which are hereby incorporated by reference in their entirety.
  • At least a portion of the external surfaces of the body, the tabs, and/or the inner surface of the head portion of the drainage device 30, 100 may be coated with a porous cellular ingrowth coating.
  • the porous cellular ingrowth coating is coated on at least the portion of the drainage device 30, 100 that is in contact with the sclera and conjunctiva when the drainage device is implanted.
  • the porous cellular ingrowth coating may be a hydro xyapatite or porous polyethylene, which serves to promote cell adhesion. Selected growth factors may be adsorbed such that the body and the tabs of the drainage device 30, 100 may be securely anchored in position. This enables the drainage device 30, 100 to resist in situ motion and displacement.
  • the body of the drainage device 30, 100 may include surface alterations, such as texturing, roughening or other patterned or non-patterned irregularities.
  • the remaining surfaces of the drainage device 30, 100 may be coated with a bio-inert surface coating to enhance surface biocompatibility.
  • a bio-inert surface coating may include bio-inert polymer coatings such as phosphoryl choline (PC), polyethylene glycol (PEG), sulfobetaine (SB), carboxybetaine (CB), and polyethylene oxide (PEO). These polymer coatings down-regulate deleterious biological reactions, primarily by attracting a large and stable hydration shell when grafted onto a surface.
  • Bio-inert surface coatings may be further modified with biologically active molecules such as heparin, spermine, surfactants, proteases or other enzymes, or other biocompatible chemicals amendable to surface immobilization.
  • biologically active molecules such as heparin, spermine, surfactants, proteases or other enzymes, or other biocompatible chemicals amendable to surface immobilization.
  • PEO also is amenable to end-group coupling for surface immobilization of the biologically active molecules.
  • the addition of such bioactive molecules could advantageously impart specific desired functionality, for example, allowing a further increase in the hydrophilicity of the surface.
  • the coating for the drainage device 30, 100 can also comprise material that includes a therapeutic agent, as well as antifibrotic and/or antimicrobial and/or anti-fouling agents.
  • the therapeutic agent can be selected from the group consisting of heparin, selenium, TGF-beta, an intraocular pressure-lowering drug, and an anti-proliferative agent.
  • the coatings can be, for example, a drug eluting coating, an
  • Antithrombogenic coating and/or a lubricious coating.
  • Materials that may be used for a drug-eluting coating include parylene C, poly(butyl methacrylate), poly(methyl methacrylate), polyethylene-co-vinyl acetate, and other materials known in the art.
  • Anti-microbial coatings may include, for example selenium, silver, melimine, or fimbrolides or other quorum sensing inhibitors.
  • these agents may be incorporated into the filter material or other components of the drainage device 30, 100 via covalent, metallic, ionic, or non-covalent bonding, or by surface adsorption.
  • Another aspect of the disclosure herein is directed to a method of manufacturing an apparatus for draining aqueous humor from an eye for reducing and/or stabilizing intraocular pressure, as shown, for example, in FIG. 17.
  • Such a method comprises engaging an outlet end of a tube into fluid communication with a cavity defined by a housing, wherein the outlet end extends to an inlet end adapted to be in fluid communication with the anterior chamber of the eye, and wherein the tube is adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end and to the outlet end such that the aqueous humor is received by the cavity (block 300).
  • a dilatable flow control device is engaged with the housing, wherein the dilatable flow control device is adapted to control the flow of the aqueous humor from the cavity to a location external to the anterior chamber, and wherein the dilatable flow control device further defines a conduit in communication between the cavity and the external location.
  • the conduit is dilatable in response to the intraocular pressure being above a preselected pressure, to increase the flow or decrease resistance to flow of the aqueous humor through the conduit to the external location and to reduce the intraocular pressure to no greater than the preselected pressure.
  • a filter device may be engaged into fluid
  • the filter device may be engaged with the housing subsequent to the outlet end of the tube, such that the flow control device is removable or replaceable with respect to the housing, so as to allow the filter device to be removed or replaced.
  • a filter device may be engaged into fluid communication with the flow control device, opposite to the outlet end of the tube from the flow control device, for filtering contaminants from any backflow to the flow control device and, in some instances, the filter device may be engaged with the housing subsequent to the flow control device, such that the filter device engaged therewith is removable or replaceable with respect to the housing.
  • the dilatable flow control device may be inserted into the cavity defined by the housing.
  • at least the portion of the flow control device defining the conduit(s) may be comprised of a material that is responsive to the output of a laser device.
  • aspects of the method may include engaging the flow control device with an output of a laser device so as to form additional dilatable conduits in the flow control device, or to seal a conduit defined by the flow control device.
  • All aspects of the drainage device 30, 100 disclosed herein may be surgically implanted under topical anesthesia, possibly supplemented subconjunctivally.
  • the drainage device 30, 100 may be inserted into the sclera using routine operative procedures.
  • the procedure for implanting the drainage device 30 includes the initial step of dissecting or piercing the conjunctiva into Tenon's space about 4 mm from the limbus in the fornix space.
  • the distal end 44 of the tube 32 is then threaded through the incision in the fornix so that the tubular body 32 passes under the conjunctiva and the outlet assembly 34 lies externally on the conjunctiva in the cul-de-sac region underneath the eyelid.
  • the conjunctiva is then dissected down from the fornix incision to the limbus to expose the underlying sclera for insertion of the distal end 44 of the tube 32.
  • a needle, trocar, scalpel, or any of a multitude of instruments familiar to ophthalmologic practitioners may be used at the site of the now exposed sclera to make a stab incision through the sclera into the anterior chamber.
  • the pointed tip at the distal end 44 of the tubular body 32 is then inserted through the scleral tract of the incision and into the anterior chamber or posterior chamber of the eye.
  • the remainder of the tubular body 32 remains positioned external to the ocular surface of the eye.
  • the tubular body 32 may be sutured to the sclera.
  • FIG. 54 Next, two parallel cuts are made into the conjunctiva adjacent the outlet assembly 34 approximately 2 mm to 4 mm apart.
  • a tab 54 is inserted into each cut.
  • the tabs 54 may be sutured to the sclera with a 10- 0 nylon suture.
  • a suture is then used to close the conjunctiva around the tabs 54 while leaving the intermediate portion of the outlet assembly 34 exposed.
  • holes may be provided in the tabs for additional sutures into the sclera, providing further stability to the drainage device 30 until the biointegration is complete.
  • the suture bars are sutured into the sclera for securing the body of the device.
  • a purse-string 8-0 suture may be used to close the conjunctiva tightly around the outlet.
  • aqueous humor flows into the drainage device 30 from the anterior chamber or posterior chamber of the eye and passes through the tubular body 32 via the lumen 46 and through the filter 40 and drains via the flow control device 39 in the outlet assembly 34.
  • the flow path through the drainage device 30 can be configured for regulating drainage of aqueous humor at a predetermined rate (i.e., as regulated by the flow-through dimensions of the flow control device) so as to regulate the intraocular pressure at or below a predetermined or preselected pressure (i.e., a threshold), and further for resisting the incursion or backflow of microorganisms to the eye.
  • the outflow of aqueous humor is consistently regulated at a preselected pressure by the filter 40 and flow control device 39, either separately or in combination, so that a predictable outflow rate or pressure response can be calculated for proper drainage for maintaining intraocular pressure at preselected pressure, generally between about 6 mmHg to about 18 mmHg and, more particularly, between about 8 mmHg and about 12 mmHg.
  • the flow rate will range based on aqueous humor production, which is usually between about 1 ⁇ and about 4 ⁇ 7 ⁇ , while avoiding hypotony, which may occur at less than about 5 mmHg.
  • an apparatus for draining aqueous humor from an eye for reducing and/or stabilizing intraocular pressure may also be provided, wherein such an apparatus 30 comprises a tube 32 extending between an inlet end and an outlet end 42, with the inlet end being adapted to be in fluid communication with the anterior chamber of the eye, and with the tube 32 being adapted to direct a flow of aqueous humor from the anterior chamber and through the inlet end to the outlet end 42.
  • a flow control device 39 is operably engaged with the outlet end 42 and is configured to control a flow of the aqueous humor from the tube 32 to a location external to the anterior chamber, wherein the flow control device 39 defines a conduit 38 in communication between the outlet end 42 and the external location, and wherein the conduit 38 is dilatable in response to the intraocular pressure being above a preselected pressure, to increase the flow or to decrease resistance to flow of the aqueous humor through the conduit 38 to the external location and to reduce the intraocular pressure to no greater than the preselected pressure.
  • a first filter device 85 is disposed in fluid communication between the inlet end of the tube and the flow control device 39, wherein the first filter device is configured to filter contaminants from the aqueous humor prior to the flow control device 39
  • a second filter device 90 is disposed in fluid communication with the flow control device 39, opposite to the outlet end 42 of the tube 32 from the flow control device 39, wherein the second filter device 90 is configured to filter contaminants from any backflow to the flow control device 39.
  • the first filter device 85 is engaged with the outlet end 42 of the tube 32, and is operably engaged with the flow control device 39, such that the flow control device 39 is removable or replaceable with respect thereto, so as to allow the first filter device 85 to be removed or replaced.
  • the second filter device 90 may be engaged with the flow control device 39 opposite to the first filter device 85, wherein the flow control device 39 is configured such that the second filter device 90 is removable or replaceable with respect thereto, so as to allow the second filter device 90 to be removed or replaced.
  • a housing defining a cavity may be in fluid communication with the outlet end of the tube, wherein the cavity is configured to receive the aqueous humor, and wherein the housing is configured to operably engage the flow control device such that the flow control device regulates the flow of the aqueous humor from the cavity.
  • the "dual filter” configuration incorporates components of the drainage device(s) as otherwise disclosed herein, particularly wherein a filter 85, 90 is disposed both upstream and downstream of the flow control device 39.
  • the dual filter configuration thus, for example, provides for filtering of the aqueous humor and preventing backflow of contaminants in regard to the drainage device, and removes the requirements regarding clogging resistance or contaminant migration from the flow control device 39 itself.
  • each of the first and second filters 85, 90 and the flow control device 39 may be configured to be individually removable and replaceable. However, different combinations of the first and second filters and the flow control device may be configured to be removable and replaceable, including all three components as a single unit.
  • the dual filter configuration having the flow control device disposed therebetween may provide a physiologic design to control and/or stabilize pressure in the eye.
  • the flow control device is implemented as an episcleral venous pressure device to provide a preselected lower pressure limit of the intraocular pressure.
  • the filters may provide resistance in the manner of the trabecular meshwork in a human eye. The combination may thus provide a natural pressure change in the eye based on diurnal changes in aqueous humor production and ocular pulse.
  • the aspects of the drainage device 30, 100 described herein effectively provide outflow characteristics which model and account for the aqueous humor dynamics of a healthy eye which may vary from person to person.
  • the aspects of the drainage device 30, 100 disclosed herein may comprise any of the materials previously disclosed.
  • the drainage device 30, 100 can be fabricated through conventional micro machining techniques or through procedures commonly used for fabricating optical fibers or semiconductors or other micro-scale or nano-scale systems.
  • the drainage devices 30, 100 are drawn with a bore, or lumen, extending therethrough.
  • the tapered tip at the distal end of the body can be constructed by shearing off an end of the tubular body. This can create the tapered portion that can be used to puncture or incise the eye tissue during implantation and dilate the puncture or incision during advancement of the drainage device 30, 100.
  • Other methods of manufacturing the drainage device 30 can be implemented, as will be appreciated by one skilled in the art.
  • Each of the aspects of the drainage device 30, 100 provides a method for treating glaucoma wherein the aqueous humor is permitted to flow out of an anterior chamber or posterior chamber of the eye through a surgically implanted pathway to a location external to the anterior or posterior chamber.
  • the drainage device 30, 100 is implanted with minimal invasiveness of the ocular tissue and minimal sense of a foreign object to the person in which it is implanted. Immobilizing the outlet assembly of the drainage device 30, 100 is an important feature. Immobilization is enhanced by using a biocompatible material and by providing the portions of the drainage device 30, 100 with the porous cellular ingrowth surface in contact with eye tissue to promote tissue integration to the sclera.
  • the embodiments of the drainage device 30, 100 as disclosed herein can be used to treat other ocular disorders, in addition to glaucoma.
  • the drainage device 30, 100 may be used to treat dry eye, wherein the aqueous humor exiting the drainage device combines with the tear film for enhancing moisture and lubrication in the eye.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)
EP16754612.6A 2015-08-14 2016-08-11 Apparatus for reducing intraocular pressure and method for manufacturing such apparatus Withdrawn EP3334395A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/826,866 US10342702B2 (en) 2014-08-29 2015-08-14 Apparatus and method for reducing intraocular pressure
PCT/US2016/046579 WO2017030902A2 (en) 2015-08-14 2016-08-11 Apparatus and method for reducing intraocular pressure

Publications (1)

Publication Number Publication Date
EP3334395A2 true EP3334395A2 (en) 2018-06-20

Family

ID=56787701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16754612.6A Withdrawn EP3334395A2 (en) 2015-08-14 2016-08-11 Apparatus for reducing intraocular pressure and method for manufacturing such apparatus

Country Status (5)

Country Link
EP (1) EP3334395A2 (enExample)
JP (1) JP2018525107A (enExample)
CN (1) CN108135739A (enExample)
CA (1) CA2995580C (enExample)
WO (1) WO2017030902A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
CN108135470B (zh) 2015-08-14 2021-03-09 伊万提斯公司 具有压力传感器和输送系统的眼部植入物
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
EP4371535A3 (en) 2018-02-22 2024-08-14 Alcon Inc. Ocular implant
DE102018203424A1 (de) * 2018-03-07 2019-09-12 Carl Zeiss Meditec Ag Shunt-Implantat
EP3846748A1 (en) * 2018-09-06 2021-07-14 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Apparatus for treating excess intraocular fluid having an elastic membrane
JP7547608B2 (ja) * 2020-07-22 2024-09-09 ナショナル ユニバーシティ ホスピタル （シンガポール） ピーティーイー エルティーディー 眼の排液インプラント
JP7220688B2 (ja) * 2020-09-16 2023-02-10 巨晰光纖股▲ふん▼有限公司 眼球排水用分流支持枠
KR20230130622A (ko) 2021-01-11 2023-09-12 알콘 인코포레이티드 점탄성 전달을 위한 시스템 및 방법
US20220313491A1 (en) * 2021-04-02 2022-10-06 Twenty Twenty Therapeutics Llc Passive intraocular pressure control and associated systems, devices, and methods
CN113974960B (zh) * 2021-10-21 2025-09-19 首都医科大学附属北京同仁医院 一种分体式房水引流装置
CN114533387A (zh) * 2022-01-14 2022-05-27 南京普立蒙医疗科技有限公司 一种青光眼治疗用的引流装置及制作方法
EP4563129A1 (en) * 2022-07-25 2025-06-04 Microt Inc. Implant device having multiple channels for eye diseases, and method for manufacturing same
US20250312193A1 (en) * 2024-04-03 2025-10-09 Alcon Inc. Intraocular pressure devices

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886488A (en) * 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method
US5171213A (en) * 1991-08-14 1992-12-15 Price Jr Francis W Technique for fistulization of the eye and an eye filtration prosthesis useful therefor
US20050119737A1 (en) * 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
US7708711B2 (en) * 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6881198B2 (en) * 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
US20060069340A1 (en) * 2003-06-16 2006-03-30 Solx, Inc. Shunt for the treatment of glaucoma
US9186274B2 (en) * 2005-02-23 2015-11-17 Camras Vision Inc. Method and apparatus for reducing intraocular pressure
US9333115B2 (en) * 2011-12-13 2016-05-10 Alcon Research, Ltd. Separation of gas and liquid in membrane valves
WO2013090231A1 (en) * 2011-12-13 2013-06-20 Alcon Research, Ltd. Active drainage systems with dual-input pressure-driven valves
CN104490515A (zh) * 2014-12-18 2015-04-08 肖真 青光眼阀和青光眼引流装置

Also Published As

Publication number Publication date
JP2018525107A (ja) 2018-09-06
CA2995580A1 (en) 2017-02-23
CA2995580C (en) 2020-03-31
CN108135739A (zh) 2018-06-08
WO2017030902A3 (en) 2017-06-29
WO2017030902A2 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
US11723804B2 (en) Device and method for reducing intraocular pressure
US10342702B2 (en) Apparatus and method for reducing intraocular pressure
CA2995580C (en) Apparatus and method for reducing intraocular pressure
US10524958B2 (en) Method and apparatus for reducing intraocular pressure
US20220395397A1 (en) New ocular device and method for glaucoma treatment
US6595945B2 (en) Glaucoma treatment device and method
US20190000673A1 (en) Ocular implants for reduction of intraocular pressure and methods for implanting same
US20080161741A1 (en) Ocular implant and methods for making and using same
US20100168644A1 (en) Glaucoma Treatment Device and Method
EP2410959A2 (en) Glaucoma shunts with flow management and improved surgical performance
AU2014280907B2 (en) Glaucoma shunts with flow management and improved surgical performance
CA2471242A1 (en) Glaucoma treatment device and method

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220302

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240301